250+
I-O
Thought Leaders
100+
Scientific Presentations
9
Days of Programming
61%
Industry
Delegates


2020 Plenary Keynote Speakers

Stanley Riddell, MD, Scientific Director, Clinical Research, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine

Roy D. Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharpe & Dohme


Additional 2020 Featured Speakers

Edith Borcoman, MD, Medical Oncologist, Institut Curie, Paris

Renier Brentjens, MD, PhD, Director, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center; Professor, Pharmacology, Weill Cornell Graduate School of Medical Sciences

Sara Colombetti, PhD, Global Head of Oncology Discovery Pharmacology, Pharma Research and Early Development (pRED), Roche Innovation Center Zurich

George Coukos, Full Professor and Director, Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL); Director, Lausanne Branch, Ludwig Institute of Cancer Research Chief, Service of Immuno-Oncology, CHUV

Lindy Durrant, PhD, Professor of Cancer immunotherapy, University of Nottingham; CSO, Scancell Ltd

Gordon J. Freeman, PhD, Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

Maria Karasarides, PhD, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals

Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart

Jeanette Leusen, PhD, Associate Professor and Head Immunotherapy Group, Translational Immunology, University Medical Centre Utrecht

Wouter Scheper, PhD, Senior Postdoc, Molecular Oncology and Immunology, Netherlands Cancer Institute

Karoline Schjetne, PhD, Vice President Scientific Affairs, Vaccibody

Hans van der Vliet, MD, PhD, CSO, LAVA Therapeutics; Medical Oncologist, Amsterdam UMC

ABOUT THE EVENT

Cambridge Healthtech Institute’s Fifth Annual Immuno-Oncology Summit Europe returns to the heart of London’s Canary Wharf for four days of cutting edge science and discussion. Through six conference tracks, delegates will hear from the research teams at the forefront of the rapidly developing field of cancer biotherapeutics.